FRA:YB3'
s Net Margin % Range Over the Past 10 Years
Min: -21.42 Med: 16.36 Max: 40.16
Current: 14.04
FRA:YB3's Net Margin % is ranked better than 85.29% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs FRA:YB3: 14.04
Shin Nippon Biomedical Laboratories (FRA:YB3) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shin Nippon Biomedical Laboratories Net Margin % Related Terms
Shin Nippon Biomedical Laboratories Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Net Margin % Chart
FRA:YB3 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (FRA:YB3) has a Net Margin % of 20.27% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is 24% above median its historical median of 16.36. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #30 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 14.7%.
Is Shin Nippon Biomedical Laboratories' Net Margin % too high?
Shin Nippon Biomedical Laboratories' current Net Margin % of 20.27% is 24% above median its 10-year median of 16.36. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #30 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #30 out of 204 companies for Net Margin %. This places Shin Nippon Biomedical Laboratories in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shin Nippon Biomedical Laboratories and its competitors. Shin Nippon Biomedical Laboratories's current Net Margin % is 20.27%, which is 24% above median its own 10-year median of 16.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (FRA:YB3) has a current Net Margin % of 20.27%. The stock's GF Value™ is €9.47, compared to a current price of €6.00 — trading 36.6% below its estimated fair value. The current Net Margin % is 20.27%, which is 24% above median its 10-year median of 16.36. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (FRA:YB3), the current Net Margin % is 20.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (FRA:YB3) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of €6.00 is trading 36.6% below its estimated GF Value™ of €9.47.
Key valuation signals for FRA:YB3:
Net Margin %: 20.27% (24% above median its 10-year median of 16.36)
GF Value™: €9.47 vs. price of €6.00 (36.6% below fair value)
No single metric tells the full story. See the FRA:YB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for FRA:YB3
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:YB3 has been successfully added to your 
